Validated by the World Health Organization's Emergency Use Listing ("EUL") Procedure on June 2, 2021

• CoronaVac^® is the first COVID-19 vaccine to be used in children as young as 3 years old, under the WHO’s Emergency Use List.

• Several published studies have shown that CoronaVac^® has a good safety profile for healthy people and people with special health conditions.

• Real-world studies indicate CoronaVac^® can effectively reduce severe illness and deaths related to COVID-19.

• As of March 2023, CoronaVac^® has been authorized for use in more than 60 countries, regions, and international organizations. The cumulative global supply exceeds 2.9 billion doses.